Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04624698 · ClinicalTrials.gov registry record · NA
iStent Inject New Enrollment Post-Approval Study
A NA study of Glaucoma and Glaucoma Open-Angle, sponsored by Glaukos Corporation.
- Active
- Registry status
- NA
- Development phase
- 358
- Enrollment target
- 3
- Study locations
NCT04624698: Active NA study of Glaucoma and Glaucoma Open-Angle, sponsored by Glaukos Corporation.
NCT04624698 is a NA study of Glaucoma and Glaucoma Open-Angle that is active but no longer recruiting, run by Glaukos Corporation. The registered enrollment target is 358 participants, below the 907-participant average among 92 other Glaucoma trials with a reported enrollment target (61% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04624698, a NA study of Glaucoma and Glaucoma Open-Angle, is active but no longer recruiting, sponsored by Glaukos Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 358 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
Conditions Studied
Interventions
- DEVICE iStent Inject Implantation
Study Locations (3)
Arizona
- Eye Doctors of Arizona, PLLC - Phoenix
California
- Wolstan and Goldberg Eye Associates - Torrance
Texas
- Glaucoma Associates of Texas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2020-09-22 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT04624698 still lists
NCT04624698 is an interventional study that assigns participants to a tested intervention. The registered 358 participants enrollment target is mid-sized for trials with a published cap, below the 907-participant average among 92 other Glaucoma trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which iStent Inject Implantation is the first listed.
NCT04624698 reports a single indexed study location in Arizona, California, Texas.
Frequently Asked Questions
What is clinical trial NCT04624698 about?
NCT04624698 is a clinical study titled "iStent Inject New Enrollment Post-Approval Study". Study to evaluate the rate of clinically relevant complications associated with iStent inject placement in the post-market setting.
What is the current status of trial NCT04624698?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 358 participants. The study started on 2020-09-22. Estimated completion is 2026-05.
What conditions does trial NCT04624698 study?
This clinical trial studies the following conditions: Glaucoma, Glaucoma Open-Angle.
What interventions are being tested in trial NCT04624698?
The interventions under investigation include: iStent Inject Implantation (DEVICE).
Who is sponsoring clinical trial NCT04624698?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04624698 being conducted?
This trial has 3 study locations across Arizona, California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04624698's enrollment target sits among peer trials
358 16th of 92 higher than 77 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04373317 · 358 participants · Phase 4
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
- NCT05684965 · 358 participants · Phase 1
XTX301 in Patients With Advanced Solid Tumors
- NCT05824975 · 358 participants · Phase 1
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- NCT06480227 · 358 participants · NA
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI